ICON plc has completed the acquisition of Aptiv Solutions for $143.5 million in cash. Aptiv, headquartered in Reston, VA, has operations in 16 countries for the design and execution of adaptive clinical trials for pharma and biopharma companies. Aptiv also manages medical device trials using its adaptive capabilities, and owns Niphix, an oncology-focused CRO serving both Japanese and international customers.
“Aptiv’s adaptive trial capabilities, combined with our existing technology platforms, such as ICONIK and Firecrest, will further differentiate our services and help our customers take time and cost out of the development process,” said Dr. Nuala Murphy, president, ICON Clinical Research Services. “Their presence in Japan and medical device capabilities will also broaden our offerings in these markets.”